ArticleANZ journal of surgery2026
Two Decades of Multimodal Management of Colorectal Liver Metastases With Long-Term Outcomes.
Article in ANZ journal of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe management of patients with colorectal liver metastases (CRLM) is complex and requires a tailored approach based on disease extent, patient age, and comorbidities. Given the heterogeneity in presentation and evolving treatment algorithms, prognostic factors for long-term survival following liver resection are contested. This study aimed to evaluate "real-world" outcomes in patients with long-term follow-up after potentially curative liver resection at a tertiary Australian center.
methodsA retrospective analysis was conducted on prospectively collected data from patients who underwent first-time liver resection for CRLM between 1998 and 2018. Standardized clinical, biochemical, and radiological follow-up was undertaken. Multivariable Cox regression analysis was used to identify independent predictors of overall survival (OS), measured from the diagnosis of liver metastases to death or last contact.
resultsOf 396 patients who underwent resection, 320 met the inclusion criteria. The median follow-up was 123.3 months (95% CI: 110.5-131.0), median OS was 69.6 months (95% CI: 57.2-84.5), and the 10-year OS rate was 33%; 5-year and 10-year disease-free survival rates were 29% and 25%, respectively. Neoadjuvant chemotherapy was administered in 72% of patients, with 25% receiving targeted therapy in this setting. Postoperative (adjuvant or recurrence-related) chemotherapy was given to 50% of patients, with 17% also receiving targeted therapy. Independent predictors of poor OS included older age, right-sided primary tumours, large liver tumours, administration of locoregional liver therapy, and the use of chemotherapy ± targeted therapy in both the neoadjuvant and adjuvant settings.
conclusionOne-third of patients who undergo liver resection for CRLM achieve long-term survival. While multi-modal therapy was commonly used, determining the specific contribution of non-surgical treatments is challenging in a real-world cohort where treatment paradigms evolved over time. This study provides rare 10-year follow-up data and reinforces the need for ongoing refinement of personalised management strategies for CRLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.